Ameriprise
COGT icon

Ameriprise’s Cogent Biosciences COGT Stock Holding History

Ameriprise’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.7M Buy
252,114
+63,765
+34% +$2.35M ﹤0.01% 1952
2025
Q4 		$6.69M Buy
+188,349
New +$5.29M ﹤0.01% 2227
2025
Q2 		– Sell
-18,165
Closed -$109K – 3989
2025
Q1 		$109K Sell
18,165
-3,334
-16% -$26.1K ﹤0.01% 3870
2024
Q4 		$168K Buy
21,499
+9,459
+79% +$94.3K ﹤0.01% 3895
2024
Q3 		$130K Buy
12,040
+35
+0.3% +$341 ﹤0.01% 3806
2024
Q2 		$101K Buy
+12,005
New +$91.1K ﹤0.01% 3775

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Ameriprise's COGT Position: Q1 2026 in Review

Ameriprise increased its Cogent Biosciences (COGT) stake by 34% in Q1 2026, buying an estimated $2.35M and bringing the position to 252,114 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Ameriprise first reported a position in COGT in Q2 2024 and has held it in 6 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Ameriprise held 252,114 shares of Cogent Biosciences worth $9.7M as of Q1 2026.
  • Ameriprise bought 63,765 Cogent Biosciences shares in Q1 2026, an estimated $2.35M.
  • Cogent Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1952 holding.
  • Ameriprise first reported a position in Cogent Biosciences in Q2 2024 and has held it in 6 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.